104 related articles for article (PubMed ID: 28653368)
1. Decrease of externalized phosphatidylserine density on red blood cell-derived microparticles in SCA patients treated with hydroxycarbamide.
Garnier Y; Ferdinand S; Connes P; Garnier M; Etienne-Julan M; Lemonne N; Romana M
Br J Haematol; 2018 Aug; 182(3):448-451. PubMed ID: 28653368
[No Abstract] [Full Text] [Related]
2. The acceleration of the propagation phase of thrombin generation in patients with steady-state sickle cell disease is associated with circulating erythrocyte-derived microparticles.
Gerotziafas GT; Van Dreden P; Chaari M; Galea V; Khaterchi A; Lionnet F; Stankovic-Stojanovic K; Blanc-Brude O; Woodhams B; Maier-Redelsperger M; Girot R; Hatmi M; Elalamy I
Thromb Haemost; 2012 Jun; 107(6):1044-52. PubMed ID: 22535498
[TBL] [Abstract][Full Text] [Related]
3. Fetal hemoglobin and hydroxycarbamide moduate both plasma concentration and cellular origin of circulating microparticles in sickle cell anemia children.
Nébor D; Romana M; Santiago R; Vachiery N; Picot J; Broquere C; Chaar V; Doumdo L; Odièvre MH; Benkerrou M; Elion J
Haematologica; 2013 Jun; 98(6):862-7. PubMed ID: 23403312
[TBL] [Abstract][Full Text] [Related]
4. Differences of microparticle patterns between sickle cell anemia and hemoglobin SC patients.
Garnier Y; Ferdinand S; Etienne-Julan M; Elana G; Petras M; Doumdo L; Tressières B; Lalanne-Mistrih ML; Hardy-Dessources MD; Connes P; Romana M
PLoS One; 2017; 12(5):e0177397. PubMed ID: 28489923
[TBL] [Abstract][Full Text] [Related]
5. Gene expression of HIF-1α and VEGF in response to hypoxia in sickle cell anaemia: Influence of hydroxycarbamide.
Pedrosa AM; Lemes RPG
Br J Haematol; 2020 Jul; 190(1):e39-e42. PubMed ID: 32352161
[TBL] [Abstract][Full Text] [Related]
6. Alpha haemoglobin-stabilising protein concentration in the red blood cells of patients with sickle cell anaemia with and without hydroxycarbamide treatment.
Vasseur C; Domingues-Hamdi E; Pakdaman S; Galactéros F; Baudin-Creuza V
Br J Haematol; 2022 Jan; 196(1):183-192. PubMed ID: 34378186
[TBL] [Abstract][Full Text] [Related]
7. Treating sickle cell anaemia with hydroxycarbamide.
Pollack S
Br J Haematol; 2014 Jan; 164(2):296-7. PubMed ID: 24116862
[No Abstract] [Full Text] [Related]
8. Effects of hydroxyurea on the membrane of erythrocytes and platelets in sickle cell anemia.
Covas DT; de Lucena Angulo I; Vianna Bonini Palma P; Zago MA
Haematologica; 2004 Mar; 89(3):273-80. PubMed ID: 15020264
[TBL] [Abstract][Full Text] [Related]
9. Hydroxycarbamide reduces eosinophil adhesion and degranulation in sickle cell anaemia patients.
Pallis FR; Conran N; Fertrin KY; Olalla Saad ST; Costa FF; Franco-Penteado CF
Br J Haematol; 2014 Jan; 164(2):286-95. PubMed ID: 24383847
[TBL] [Abstract][Full Text] [Related]
10. Therapy with hydroxyurea is associated with reduced adhesion molecule gene and protein expression in sickle red cells with a concomitant reduction in adhesive properties.
Gambero S; Canalli AA; Traina F; Albuquerque DM; Saad ST; Costa FF; Conran N
Eur J Haematol; 2007 Feb; 78(2):144-51. PubMed ID: 17313560
[TBL] [Abstract][Full Text] [Related]
11. Hydroxycarbamide treatment and brain MRI/MRA findings in children with sickle cell anaemia.
Nottage KA; Ware RE; Aygun B; Smeltzer M; Kang G; Moen J; Wang WC; Hankins JS; Helton KJ
Br J Haematol; 2016 Oct; 175(2):331-338. PubMed ID: 27604981
[TBL] [Abstract][Full Text] [Related]
12. Additive effect of sirolimus and hydroxycarbamide on fetal haemoglobin level in kidney transplant patients with sickle cell disease.
Al-Khatti AA; Alkhunaizi AM
Br J Haematol; 2019 Jun; 185(5):959-961. PubMed ID: 30407620
[No Abstract] [Full Text] [Related]
13. Feasibility and benefit of hydroxycarbamide as a long-term treatment for sickle cell disease patients: results from the North West London Sickle Cell Disease Registry.
Gilmore A; Cho G; Howard J; Layton M; Afif M; Hughes RG; Philpott NJ; Patankar S; Davies SC;
Am J Hematol; 2011 Nov; 86(11):958-61. PubMed ID: 21948113
[No Abstract] [Full Text] [Related]
14. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
[TBL] [Abstract][Full Text] [Related]
15. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
Loukopoulos D; Voskaridou E; Kalotychou V; Schina M; Loutradi A; Theodoropoulos I
Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383
[TBL] [Abstract][Full Text] [Related]
16. Hydroxycarbamide use in young children with sickle-cell anaemia.
Takahashi Y; Mori J; Tsubokura M; Matsumura T; Kami M
Lancet; 2011 Nov; 378(9805):1777. PubMed ID: 22098851
[No Abstract] [Full Text] [Related]
17. Hydroxycarbamide use in young children with sickle-cell anaemia.
Obaro SK; Inusa B; Telfer P
Lancet; 2011 Nov; 378(9805):1777. PubMed ID: 22098850
[No Abstract] [Full Text] [Related]
18. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia.
Ballas SK; McCarthy WF; Guo N; Brugnara C; Kling G; Bauserman RL; Waclawiw MA
Hemoglobin; 2010; 34(5):424-9. PubMed ID: 20854115
[TBL] [Abstract][Full Text] [Related]
19. Elevated plasma levels and platelet-associated expression of the pro-thrombotic and pro-inflammatory protein, TNFSF14 (LIGHT), in sickle cell disease.
Garrido VT; Proença-Ferreira R; Dominical VM; Traina F; Bezerra MA; de Mello MR; Colella MP; Araújo AS; Saad ST; Costa FF; Conran N
Br J Haematol; 2012 Sep; 158(6):788-97. PubMed ID: 22775554
[TBL] [Abstract][Full Text] [Related]
20. Red blood cells microparticles are associated with hemolysis markers and may contribute to clinical events among sickle cell disease patients.
Olatunya OS; Lanaro C; Longhini AL; Penteado CFF; Fertrin KY; Adekile A; Saad STO; Costa FF
Ann Hematol; 2019 Nov; 98(11):2507-2521. PubMed ID: 31493004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
